[TABLE OF CONTENTS]

1 INTRODUCTION OF ASIA PACIFIC EUBIOTICS MARKET
1.1 OVERVIEW OF THE MARKET
1.2 SCOPE OF REPORT
1.3 ASSUMPTIONS

2 EXECUTIVE SUMMARY: ASIA PACIFIC EUBIOTICS MARKET

3 RESEARCH METHODOLOGY
3.1 DATA MINING
3.2 VALIDATION
3.3 PRIMARY INTERVIEWS
3.4 LIST OF DATA SOURCES
3.5 ANALYST TOOLS AND MODELS

4 ASIA PACIFIC EUBIOTICS MARKET OUTLOOK
4.1 OVERVIEW
4.2 MARKET DYNAMICS AND TRENDS
4.2.1 DRIVERS
4.2.2 RESTRAINTS
4.2.3 OPPORTUNITIES
4.3 PORTERS FIVE FORCE ANALYSIS
4.4 VALUE CHAIN ANALYSIS
4.5 MARKET GROWTH AND OUTLOOK
4.5.1 PRICE TREND ANALYSIS
4.5.2 OPPORTUNITY SHARE

5 ASIA PACIFIC EUBIOTICS MARKET, BY TYPE
5.1 OVERVIEW
5.2 PROBIOTICS
5.2.1 LACTOBACILLI
5.2.2 BIFIDOBACTERIA
5.2.3 OTHERS
5.3 PREBIOTICS
5.3.1 INULIN
5.3.2 FRUCTO-OLIGOSACCHARIDES
5.3.3 GALACTO-OLIGOSACCHARIDES
5.3.4 OTHERS
5.4 ORGANIC ACIDS
5.5 ESSENTIAL OILS

6 ASIA PACIFIC EUBIOTICS MARKET, BY GEOGRAPHY
6.1 OVERVIEW

6.2 ASIA PACIFIC

6.2.1 ASIA PACIFIC MARKET SNAPSHOT
6.2.2 CHINA
6.2.3 INDIA
6.2.4 INDONESIA
6.2.5 THAILAND
6.2.6 JAPAN
6.2.7 SOUTH KOREA
6.2.8 AUSTRALIA
6.2.9 REST OF ASIA-PACIFIC

7 ASIA PACIFIC EUBIOTICS MARKET COMPETITIVE LANDSCAPE
7.1 OVERVIEW
7.2 COMPANY MARKET RANKING
7.3 KEY DEVELOPMENT STRATEGIES
7.4 COMPETITIVE DASHBOARD
7.5 PRODUCT MAPPING
7.6 TOP PLAYER POSITIONING, 2022
7.7 COMPETITIVE HEATMAP
7.8 TOP WINNING STRATEGIES

8 COMPANY PROFILES

8.1 LIFE PRODUCTS, INC
8.1.1 OVERVIEW
8.1.2 FINANCIAL PERFORMANCE
8.1.3 PRODUCT OUTLOOK
8.1.4 KEY DEVELOPMENTS
8.1.5 KEY STRATEGIC MOVES AND DEVELOPMENTS

8.2 CALPIS CO. LTD
8.2.1 OVERVIEW
8.2.2 FINANCIAL PERFORMANCE
8.2.3 PRODUCT OUTLOOK
8.2.4 KEY DEVELOPMENTS
8.2.5 KEY STRATEGIC MOVES AND DEVELOPMENTS

8.3 CHR. HANSEN A/S
8.3.1 OVERVIEW
8.3.2 FINANCIAL PERFORMANCE
8.3.3 PRODUCT OUTLOOK
8.3.4 KEY DEVELOPMENTS
8.3.5 KEY STRATEGIC MOVES AND DEVELOPMENTS

8.4 LALLEMAND, INC
8.4.1 OVERVIEW
8.4.2 FINANCIAL PERFORMANCE
8.4.3 PRODUCT OUTLOOK
8.4.4 KEY DEVELOPMENTS
8.4.5 KEY STRATEGIC MOVES AND DEVELOPMENTS

8.5 DANISCO A/S
8.5.1 OVERVIEW
8.5.2 FINANCIAL PERFORMANCE
8.5.3 PRODUCT OUTLOOK
8.5.4 KEY DEVELOPMENTS
8.5.5 KEY STRATEGIC MOVES AND DEVELOPMENTS

8.6 DSM NUTRITIONAL PRODUCTS
8.6.1 OVERVIEW
8.6.2 FINANCIAL PERFORMANCE
8.6.3 PRODUCT OUTLOOK
8.6.4 KEY DEVELOPMENTS
8.6.5 KEY STRATEGIC MOVES AND DEVELOPMENTS

8.7 ORFFA INTERNATIONAL HOLDING B.V.
8.7.1 OVERVIEW
8.7.2 FINANCIAL PERFORMANCE
8.7.3 PRODUCT OUTLOOK
8.7.4 KEY DEVELOPMENTS
8.7.5 KEY STRATEGIC MOVES AND DEVELOPMENTS

8.8 NOVUS INTERNATIONAL, INC
8.8.1 OVERVIEW
8.8.2 FINANCIAL PERFORMANCE
8.8.3 PRODUCT OUTLOOK
8.8.4 KEY DEVELOPMENTS
8.8.5 KEY STRATEGIC MOVES AND DEVELOPMENTS

8.9 KEMIN INDUSTRIES, INC
8.9.1 OVERVIEW
8.9.2 FINANCIAL PERFORMANCE
8.9.3 PRODUCT OUTLOOK
8.9.4 KEY DEVELOPMENTS
8.9.5 KEY STRATEGIC MOVES AND DEVELOPMENTS

8.10 BIOVET JOINT STOCK COMPANY
8.10.1 OVERVIEW
8.10.2 FINANCIAL PERFORMANCE
8.10.3 PRODUCT OUTLOOK
8.10.4 KEY DEVELOPMENTS
8.10.5 KEY STRATEGIC MOVES AND DEVELOPMENTS

8.11 BIOMIN HOLDING GMBH
8.11.1 OVERVIEW
8.11.2 FINANCIAL PERFORMANCE
8.11.3 PRODUCT OUTLOOK
8.11.4 KEY DEVELOPMENTS
8.11.5 KEY STRATEGIC MOVES AND DEVELOPMENTS

8.12 BLUESTAR ADISSEO COMPANY
8.12.1 OVERVIEW
8.12.2 FINANCIAL PERFORMANCE
8.12.3 PRODUCT OUTLOOK
8.12.4 KEY DEVELOPMENTS
8.12.5 KEY STRATEGIC MOVES AND DEVELOPMENTS